Iovance Biotherapeutics’ Amtagvi study data shows 49 per cent response rate for commercialisation: San Carlos, California Thursday, July 17, 2025, 12:00 Hrs [IST] Iovance Biothe ...

Results from a retrospective study found that Amtagvi (lifileucel) achieved a 48.8% objective response rate in patients with ...

Iovance Biotherapeutics has hired Corleen Roche as the biotechnology company's new chief financial officer, effective Aug. 6. Iovance on Tuesday said Roche, 59 years old, most recently served as ...

Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and ...

The response rate to Amtagvi was higher in patients who had received two or fewer therapies than in those with more heavily ...

Iovance Biotherapeutics has proven to be an innovative biotech. Over the past two years, Iovance Biotherapeutics (NASDAQ: ...

S hares of Iovance Biotherapeutics (NASDAQ: IOVA) have collapsed by about 47% from the peak they reached shortly after the company's first drug earned approval this February. Unfortunately, one of ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a clinical-stage biopharmaceutical firm that has developed a revolutionary method of treating cancer by utilizing medicines that are tailored to each ...

It's been a wild roller-coaster ride for Iovance Biotherapeutics (NASDAQ: IOVA). In February, the stock more than doubled in price, then it fell to a 52-week low in July. The stock has since ...

Iovance Biotherapeutics (IOVA) has appointed Corleen Roche as chief financial officer, effective August 6th, 2025. IOVA -5.97% premarket to $1.89. Source: Press ...

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.